Psyence Biomedical Ltd.
PBMNASDAQHealthcareBiotechnology
Previous close
$4.33
+$0.40 · +10.18%
PBM company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
43
Fair Value
Momentum
17
Strong Down
Sentiment
54
Mixed
Risk resilience
25
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websitePsyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- CA
- CEO
- Jody Aufrichtig
- Listed since
- Dec 10, 2021
- Employees
- 12
Market position
Day range
Current $4.33
52-week range
Current $4.33
- Open
- $4.00
- Previous close
- $3.93
- Volume
- 103.39K
- 1.09× average
- Average volume
- 94.53K
- Average daily volume
- Market cap
- 82.35K USD
- Beta
- 1.67
- Market reference 1
- 50-day average
- $3.2188
- +34.52% above average
- 200-day average
- $18.2304
- -76.25% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -7.44M USD
- EV / EBITDA
- 1.08×
- Earnings yield
- 0.00%
- Free cash flow yield
- 0.00%
Profitability & efficiency
- Return on equity
- -40.94%
- Return on assets
- -39.48%
- Return on invested capital
- -36.81%
Financial health
- Current ratio
- 14.62×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 4.27K USD | 240 USD | — | — |
| Gross profit | — | −4.27K USD | −240 USD | — | — |
| Research and development | 1.47M USD | 342.17K USD | 954.59K USD | 1.61M USD | 137.24K USD |
| Selling, general, and administrative | 4.77M USD | 3.32M USD | 1.8M USD | 1.63M USD | 1.72M USD |
| Operating expenses | 6.24M USD | 3.66M USD | 2.75M USD | 1.29M USD | 334.29K USD |
| Interest income | 263.37K USD | 95.79K USD | 2.13K USD | 1.55K USD | 2.42K USD |
| Interest expense | 9.52K USD | 9.27K USD | 52.94K USD | — | — |
| Depreciation and amortization | 5.27K USD | 4.27K USD | 240 USD | — | 2.32M USD |
| Operating income | −6.24M USD | −3.66M USD | −2.75M USD | −4.38M USD | −334.29K USD |
| Net income | −6.94M USD | 1.01M USD | −51.16M USD | 8.01M USD | 8.23M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- 0
- FY2025 · -100.00% year over year
- Latest fiscal-year revenue
- 0 USD
- FY2025
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
PBM news
PBM peers
ETFs holding PBM
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research PBMresearch.disclaimer